New era of lipid-lowering drugs

Pharmacological Reviews

Volumn 68, Issue 2, 2016, Pages 458-475

  Barter, Philip J ^a   Rye, Kerry Anne ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE CITRATE SYNTHASE INHIBITOR; ANTILIPEMIC AGENT; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; APOLIPOPROTEIN C3; BILE ACID SEQUESTRANT; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; KEXIN; LIPOPROTEIN; LIPOPROTEIN A; MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN INHIBITOR; MONOCLONAL ANTIBODY; NICOTINIC ACID; OMEGA 3 FATTY ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; SERINE PROTEINASE INHIBITOR; SUBTILISIN; SUBTILISIN ANTIBODY; UNCLASSIFIED DRUG;

ATHEROGENESIS; CARDIOVASCULAR RISK; CHOLESTEROL SYNTHESIS; CORONARY ARTERY ATHEROSCLEROSIS; DRUG TARGETING; ENZYME RECONSTITUTION; FAMILIAL HYPOBETALIPOPROTEINEMIA; GENE MUTATION; GENE SILENCING; GENETIC VARIABILITY; HUMAN; LIPID BLOOD LEVEL; MAXIMUM TOLERATED DOSE; NONHUMAN; PHARMACEUTICAL CARE; PHARMACODYNAMICS; PHARMACOGENETICS; PRIORITY JOURNAL; RABBIT; REGULATORY MECHANISM; REVIEW; ANIMAL; CARDIOVASCULAR DISEASES; METABOLISM;

ANIMALS; CARDIOVASCULAR DISEASES; HUMANS; HYPOLIPIDEMIC AGENTS; LIPOPROTEINS;

EID: 84961262792     PISSN: 00316997     EISSN: 15210081     Source Type: Journal    
DOI: 10.1124/pr.115.012203     Document Type: Review

References (171)

1. Abifadel M, Varret M, Rabès JP, Allard D, Ouguerram K, Devillers M, Cruaud C, Benjannet S, Wickham L, and Erlich D, et al. (2003) Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet 34: 154-156.
2. Akdim F, Stroes ES, Sijbrands EJ, Tribble DL, Trip MD, Jukema JW, Flaim JD, Su J, Yu R, and Baker BF, et al. (2010a) Efficacy and safety of mipomersen, an antisense inhibitor of apolipoprotein B, in hypercholesterolemic subjects receiving stable statin therapy. J Am Coll Cardiol 55: 1611-1618.
3. Akdim F, Visser ME, Tribble DL, Baker BF, Stroes ES, Yu R, Flaim JD, Su J, Stein EA, and Kastelein JJ (2010b) Effect of mipomersen, an apolipoprotein B synthesis inhibitor, on low-density lipoprotein cholesterol in patients with familial hypercholesterolemia. Am J Cardiol 105: 1413-1419.
4. Altomonte J, Cong L, Harbaran S, Richter A, Xu J, Meseck M, and Dong HH (2004) Foxo1 mediates insulin action on apoC-III and triglyceride metabolism. J Clin Invest 114: 1493-1503.
5. Badimon JJ, Badimon L, and Fuster V (1990) Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit. J Clin Invest 85: 1234-1241.
6. Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, and Simes J, et al.; Cholesterol Treatment Trialists' (CTT) Collaboration (2010) Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170, 000 participants in 26 randomised trials. Lancet 376: 1670-1681.
7. Ballantyne CM, Davidson MH, Macdougall DE, Bays HE, Dicarlo LA, Rosenberg NL, Margulies J, and Newton RS (2013) Efficacy and safety of a novel dual modulator of adenosine triphosphate-citrate lyase and adenosine monophosphate-activated protein kinase in patients with hypercholesterolemia: results of a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial. J Am Coll Cardiol 62: 1154-1162.
8. Ballantyne CM, Neutel J, Cropp A, Duggan W, Wang EQ, Plowchalk D, Sweeney K, Kaila N, Vincent J, and Bays H (2015) Results of bococizumab, a monoclonal antibody against proprotein convertase subtilisin/kexin type 9, from a randomized, placebo-controlled, dose-ranging study in statin-treated subjects with hypercholesterolemia. Am J Cardiol 115: 1212-1221.
9. Barter P (2009) Lessons learned from the Investigation of Lipid Level Management to Understand Its Impact in Atherosclerotic Events (ILLUMINATE) trial. Am J Cardiol 104 (Suppl): 10E-15E.
10. Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, Lopez-Sendon J, Mosca L, Tardif JC, and Waters DD, et al.; ILLUMINATE Investigators (2007) Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 357: 2109-2122.
11. Barter PJ and Rye KA (2008) Is there a role for fibrates in the management of dyslipidemia in the metabolic syndrome? Arterioscler Thromb Vasc Biol 28: 39-46.
12. Barter PJ and Rye KA (2012) Cholesteryl ester transfer protein inhibition as a strategy to reduce cardiovascular risk. J Lipid Res 53: 1755-1766.
13. Benjannet S, Rhainds D, Essalmani R, Mayne J, Wickham L, Jin W, Asselin MC, Hamelin J, Varret M, and Allard D, et al. (2004) NARC-1/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol. J Biol Chem 279: 48865-48875.
14. Benn M, Nordestgaard BG, Grande P, Schnohr P, and Tybjaerg-Hansen A (2010) PCSK9 R46L, low-density lipoprotein cholesterol levels, and risk of ischemic heart disease: 3 independent studies and meta-analyses. J Am Coll Cardiol 55: 2833-2842.
15. Bergmark C, Dewan A, Orsoni A, Merki E, Miller ER, Shin MJ, Binder CJ, Hörkkö S, Krauss RM, and Chapman MJ, et al. (2008) A novel function of lipoprotein [a] as a preferential carrier of oxidized phospholipids in human plasma. J Lipid Res 49: 2230-2239.
16. Besler C, Heinrich K, Rohrer L, Doerries C, Riwanto M, Shih DM, Chroni A, Yonekawa K, Stein S, and Schaefer N, et al. (2011) Mechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery disease. J Clin Invest 121: 2693-2708.
17. Bezafibrate Infarction Prevention Study Group (2000) Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. Circulation 102: 21-27.
18. Billman GE, Hallaq H, and Leaf A (1994) Prevention of ischemia-induced ventricular fibrillation by omega 3 fatty acids. Proc Natl Acad Sci USA 91: 4427-4430.
19. Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-Nickens P, Koprowicz K, McBride R, Teo K, and Weintraub W; AIM-HIGH Investigators (2011) Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 365: 2255-2267.
20. Boekholdt SM, Sacks FM, Jukema JW, Shepherd J, Freeman DJ, McMahon AD, Cambien F, Nicaud V, de Grooth GJ, and Talmud PJ, et al. (2005) Cholesteryl ester transfer protein TaqIB variant, high-density lipoprotein cholesterol levels, cardiovascular risk, and efficacy of pravastatin treatment: individual patient metaanalysis of 13, 677 subjects. Circulation 111: 278-287.
21. Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, Darius H, Lewis BS, Ophuis TO, and Jukema JW, et al.; IMPROVE-IT Investigators (2015) Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 372: 2387-2397.
22. Careskey HE, Davis RA, Alborn WE, Troutt JS, Cao G, and Konrad RJ (2008) Atorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9. J Lipid Res 49: 394-398.
23. Casquero AC, Berti JA, Salerno AG, Bighetti EJ, Cazita PM, Ketelhuth DF, Gidlund M, and Oliveira HC (2006) Atherosclerosis is enhanced by testosterone deficiency and attenuated by CETP expression in transgenic mice. J Lipid Res 47: 1526-1534.
24. Catapano AL and Papadopoulos N (2013) The safety of therapeutic monoclonal antibodies: implications for cardiovascular disease and targeting the PCSK9 pathway. Atherosclerosis 228: 18-28.
25. Cazita PM, Berti JA, Aoki C, Gidlund M, Harada LM, Nunes VS, Quintão EC, and Oliveira HC (2003) Cholesteryl ester transfer protein expression attenuates atherosclerosis in ovariectomized mice. J Lipid Res 44: 33-40.
26. Cefalù AB, Norata GD, Ghiglioni DG, Noto D, Uboldi P, Garlaschelli K, Baragetti A, Spina R, Valenti V, and Pederiva C, et al. (2015) Homozygous familial hypobetalipoproteinemia: two novel mutations in the splicing sites of apolipoprotein B gene and review of the literature. Atherosclerosis 239: 209-217.
27. Clark RW, Ruggeri RB, Cunningham D, and Bamberger MJ (2006) Description of the torcetrapib series of cholesteryl ester transfer protein inhibitors, including mechanism of action. J Lipid Res 47: 537-552.
28. Clarke R, Peden JF, Hopewell JC, Kyriakou T, Goel A, Heath SC, Parish S, Barlera S, Franzosi MG, and Rust S, et al.; PROCARDIS Consortium (2009) Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med 361: 2518-2528.
29. Cohen J, Pertsemlidis A, Kotowski IK, Graham R, Garcia CK, and Hobbs HH (2005) Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat Genet 37: 161-165.
30. Cohen SY, Dubois L, Tadayoni R, Delahaye-Mazza C, Debibie C, and Quentel G (2007) Prevalence of reticular pseudodrusen in age-related macular degeneration with newly diagnosed choroidal neovascularisation. Br J Ophthalmol 91: 354-359.
31. Connelly MA, Parry TJ, Giardino EC, Huang Z, Cheung WM, Chen C, Cools F, Van der Linde H, Gallacher DJ, and Kuo GH, et al. (2010) Torcetrapib produces endothelial dysfunction independent of cholesteryl ester transfer protein inhibition. J Cardiovasc Pharmacol 55: 459-468.
32. Coronary Drug Project Research Group (1975) Clofibrate and niacin in coronary heart disease. JAMA 231: 360-381.
33. Cramer CT, Goetz B, Hopson KL, Fici GJ, Ackermann RM, Brown SC, Bisgaier CL, Rajeswaran WG, Oniciu DC, and Pape ME (2004) Effects of a novel dual lipid synthesis inhibitor and its potential utility in treating dyslipidemia and metabolic syndrome. J Lipid Res 45: 1289-1301.
34. Crosby J, Peloso GM, Auer PL, Crosslin DR, Stitziel NO, Lange LA, Lu Y, Tang ZZ, Zhang H, and Hindy G, et al.; TG and HDL Working Group of the Exome Sequencing Project, National Heart, Lung, and Blood Institute (2014) Loss-of-function mutations in APOC3, triglycerides, and coronary disease. N Engl J Med 371: 22-31.
35. Cuchel M, Meagher EA, du Toit Theron H, Blom DJ, Marais AD, Hegele RA, Averna MR, Sirtori CR, Shah PK, and Gaudet D, et al.; Phase 3 HoFH Lomitapide Study investigators (2013) Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study. Lancet 381: 40-46.
36. Cunningham D, Danley DE, Geoghegan KF, Griffor MC, Hawkins JL, Subashi TA, Varghese AH, Ammirati MJ, Culp JS, and Hoth LR, et al. (2007) Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia. Nat Struct Mol Biol 14: 413-419.
37. Davidson MH (2006) Mechanisms for the hypotriglyceridemic effect of marine omega-3 fatty acids. Am J Cardiol 98: 27i-33i.
38. Di Angelantonio E, Sarwar N, Perry P, Kaptoge S, Ray KK, Thompson A, Wood AM, Lewington S, Sattar N, and Packard CJ, et al.; Emerging Risk Factors Collaboration (2009) Major lipids, apolipoproteins, and risk of vascular disease. JAMA 302: 1993-2000.
39. Di Bartolo BA, Nicholls SJ, Bao S, Rye KA, Heather AK, Barter PJ, and Bursill C (2011) The apolipoprotein A-I mimetic peptide ETC-642 exhibits antiinflammatory properties that are comparable to high density lipoproteins. Atherosclerosis 217: 395-400.
40. Dietschy JM, Turley SD, and Spady DK (1993) Role of liver in the maintenance of cholesterol and low density lipoprotein homeostasis in different animal species, including humans. J Lipid Res 34: 1637-1659.
41. Drayna D, Jarnagin AS, McLean J, Henzel W, Kohr W, Fielding C, and Lawn R (1987) Cloning and sequencing of human cholesteryl ester transfer protein cDNA. Nature 327: 632-634.
42. Du XM, Kim MJ, Hou L, Le Goff W, Chapman MJ, Van Eck M, Curtiss LK, Burnett JR, Cartland SP, and Quinn CM, et al. (2015) HDL particle size is a critical determinant of ABCA1-mediated macrophage cellular cholesterol export. Circ Res 116: 1133-1142.
43. Duverger N, Kruth H, Emmanuel F, Caillaud JM, Viglietta C, Castro G, Tailleux A, Fievet C, Fruchart JC, and Houdebine LM, et al. (1996) Inhibition of atherosclerosis development in cholesterol-fed human apolipoprotein A-I-transgenic rabbits. Circulation 94: 713-717.
44. Elshourbagy NA, Near JC, Kmetz PJ, Sathe GM, Southan C, Strickler JE, Gross M, Young JF, Wells TN, and Groot PH (1990) Rat ATP citrate-lyase. Molecular cloning and sequence analysis of a full-length cDNA and mRNA abundance as a function of diet, organ, and age. J Biol Chem 265: 1430-1435.
45. Erqou S, Kaptoge S, Perry PL, Di Angelantonio E, Thompson A, White IR, Marcovina SM, Collins R, Thompson SG, and Danesh J; Emerging Risk Factors Collaboration (2009) Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA 302: 412-423.
46. Favari E, Calabresi L, Adorni MP, Jessup W, Simonelli S, Franceschini G, and Bernini F (2009) Small discoidal pre-beta1 HDL particles are efficient acceptors of cell cholesterol via ABCA1 and ABCG1. Biochemistry 48: 11067-11074.
47. Föger B, Chase M, Amar MJ, Vaisman BL, Shamburek RD, Paigen B, Fruchart-Najib J, Paiz JA, Koch CA, and Hoyt RF, et al. (1999) Cholesteryl ester transfer protein corrects dysfunctional high density lipoproteins and reduces aortic atherosclerosis in lecithin cholesterol acyltransferase transgenic mice. J Biol Chem 274: 36912-36920.
48. Forrest MJ, Bloomfield D, Briscoe RJ, Brown PN, Cumiskey AM, Ehrhart J, Hershey JC, Keller WJ, Ma X, and McPherson HE, et al. (2008) Torcetrapibinduced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone. Br J Pharmacol 154: 1465-1473.
49. Frank-Kamenetsky M, Grefhorst A, Anderson NN, Racie TS, Bramlage B, Akinc A, Butler D, Charisse K, Dorkin R, and Fan Y, et al. (2008) Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates. Proc Natl Acad Sci USA 105: 11915-11920.
50. Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, Huttunen JK, Kaitaniemi P, Koskinen P, and Manninen V, et al. (1987) Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 317: 1237-1245.
51. Fruchart JC (2013) Selective peroxisome proliferator-activated receptor a modulators (SPPARMa): the next generation of peroxisome proliferator-activated receptor a-agonists. Cardiovasc Diabetol 12: 82.
52. Gaudet D, Alexander VJ, Baker BF, Brisson D, Tremblay K, Singleton W, Geary RS, Hughes SG, Viney NJ, and Graham MJ, et al. (2015) Antisense inhibition of apolipoprotein C-III in patients with hypertriglyceridemia. N Engl J Med 373: 438-447.
53. Gaudet D, Brisson D, Tremblay K, Alexander VJ, Singleton W, Hughes SG, Geary RS, Baker BF, Graham MJ, and Crooke RM, et al. (2014) Targeting APOC3 in the familial chylomicronemia syndrome. N Engl J Med 371: 2200-2206.
54. Ginsberg HN, Elam MB, Lovato LC, Crouse JR 3rd, Leiter LA, Linz P, Friedewald WT, Buse JB, Gerstein HC, and Probstfield J, et al. ACCORD Study Group (2010) Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 362: 1563-1574.
55. Giugliano RP, Desai NR, Kohli P, Rogers WJ, Somaratne R, Huang F, Liu T, Mohanavelu S, Hoffman EB, and McDonald ST, et al.; LAPLACE-TIMI 57 Investigators (2012) Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebocontrolled, dose-ranging, phase 2 study. Lancet 380: 2007-2017.
56. Goldstein JL, Brown MS, Anderson RG, Russell DW, and Schneider WJ (1985) Receptor-mediated endocytosis: concepts emerging from the LDL receptor system. Annu Rev Cell Biol 1: 1-39.
57. Graham MJ, Lee RG, Bell TA 3rd, Fu W, Mullick AE, Alexander VJ, Singleton W, Viney N, Geary R, and Su J, et al. (2013) Antisense oligonucleotide inhibition of apolipoprotein C-III reduces plasma triglycerides in rodents, nonhuman primates, and humans. Circ Res 112: 1479-1490.
58. Gupta N, Fisker N, Asselin MC, Lindholm M, Rosenbohm C, Ørum H, Elmén J, Seidah NG, and Straarup EM (2010) A locked nucleic acid antisense oligonucleotide (LNA) silences PCSK9 and enhances LDLR expression in vitro and in vivo. PLoS One 5: e10682.
59. Ha YC and Barter PJ (1982) Differences in plasma cholesteryl ester transfer activity in sixteen vertebrate species. Comp Biochem Physiol B 71: 265-269.
60. Hayek T, Masucci-Magoulas L, Jiang X, Walsh A, Rubin E, Breslow JL, and Tall AR (1995) Decreased early atherosclerotic lesions in hypertriglyceridemic mice expressing cholesteryl ester transfer protein transgene. J Clin Invest 96: 2071-2074.
61. Heller F and Harvengt C (1983) Effects of clofibrate, bezafibrate, fenofibrate and probucol on plasma lipolytic enzymes in normolipaemic subjects. Eur J Clin Pharmacol 25: 57-63.
62. Herrera VL, Makrides SC, Xie HX, Adari H, Krauss RM, Ryan US, and Ruiz-Opazo N (1999) Spontaneous combined hyperlipidemia, coronary heart disease and decreased survival in Dahl salt-sensitive hypertensive rats transgenic for human cholesteryl ester transfer protein. Nat Med 5: 1383-1389.
63. Hesler CB, Swenson TL, and Tall AR (1987) Purification and characterization of a human plasma cholesteryl ester transfer protein. J Biol Chem 262: 2275-2282.
64. Hildebrand RB, Lammers B, Meurs I, Korporaal SJ, De Haan W, Zhao Y, Kruijt JK, Praticò D, Schimmel AW, and Holleboom AG, et al. (2010) Restoration of high-density lipoprotein levels by cholesteryl ester transfer protein expression in scavenger receptor class B type I (SR-BI) knockout mice does not normalize pathologies associated with SR-BI deficiency. Arterioscler Thromb Vasc Biol 30: 1439-1445.
65. Horton JD, Cohen JC, and Hobbs HH (2007) Molecular biology of PCSK9: its role in LDL metabolism. Trends Biochem Sci 32: 71-77.
66. Horton JD, Cohen JC, and Hobbs HH (2009) PCSK9: a convertase that coordinates LDL catabolism. J Lipid Res 50 (Suppl): S172-S177.
67. Hovingh GK, Kastelein JJ, van Deventer SJ, Round P, Ford J, Saleheen D, Rader DJ, Brewer HB, and Barter PJ (2015) Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet 386: 452-460.
68. Hu X, Dietz JD, Xia C, Knight DR, Loging WT, Smith AH, Yuan H, Perry DA, and Keiser J (2009) Torcetrapib induces aldosterone and cortisol production by an intracellular calcium-mediated mechanism independently of cholesteryl ester transfer protein inhibition. Endocrinology 150: 2211-2219.
69. Huang S, Henry L, Ho YK, Pownall HJ, and Rudenko G (2010) Mechanism of LDL binding and release probed by structure-based mutagenesis of the LDL receptor. J Lipid Res 51: 297-308.
70. Jensen MK, Rimm EB, Furtado JD, and Sacks FM (2012) Apolipoprotein C-III as a potential modulator of the association between HDL-cholesterol and incident coronary heart disease. J Am Heart Assoc 1: e000232.
71. Jeong HJ, Lee HS, Kim KS, Kim YK, Yoon D, and Park SW (2008) Sterol-dependent regulation of proprotein convertase subtilisin/kexin type 9 expression by sterolregulatory element binding protein-2. J Lipid Res 49: 399-409.
72. Johannsen TH, Frikke-Schmidt R, Schou J, Nordestgaard BG, and Tybjærg-Hansen A (2012) Genetic inhibition of CETP, ischemic vascular disease and mortality, and possible adverse effects. J Am Coll Cardiol 60: 2041-2048.
73. Jong MC, Hofker MH, and Havekes LM (1999) Role of ApoCs in lipoprotein metabolism: functional differences between ApoC1, ApoC2, and ApoC3. Arterioscler Thromb Vasc Biol 19: 472-484.
74. Jørgensen AB, Frikke-Schmidt R, Nordestgaard BG, and Tybjærg-Hansen A (2014) Loss-of-function mutations in APOC3 and risk of ischemic vascular disease. N Engl J Med 371: 32-41.
75. Kamstrup PR, Tybjærg-Hansen A, and Nordestgaard BG (2014) Elevated lipoprotein (a) and risk of aortic valve stenosis in the general population. J Am Coll Cardiol 63: 470-477.
76. Kastelein JJ, Wedel MK, Baker BF, Su J, Bradley JD, Yu RZ, Chuang E, Graham MJ, and Crooke RM (2006) Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B. Circulation 114: 1729-1735.
77. Kawakami A, Aikawa M, Alcaide P, Luscinskas FW, Libby P, and Sacks FM (2006a) Apolipoprotein CIII induces expression of vascular cell adhesion molecule-1 in vascular endothelial cells and increases adhesion of monocytic cells. Circulation 114: 681-687.
78. Kawakami A, Aikawa M, Libby P, Alcaide P, Luscinskas FW, and Sacks FM (2006b) Apolipoprotein CIII in apolipoprotein B lipoproteins enhances the adhesion of human monocytic cells to endothelial cells. Circulation 113: 691-700.
79. Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, Forder P, Pillai A, Davis T, and Glasziou P, et al.; FIELD Study Investigators (2005) Effects of longterm fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366: 1849-1861.
80. Khera AV, Millar JS, Ruotolo G, Wang MD, and Rader DJ (2015) Potent peroxisome proliferator-activated receptor-a agonist treatment increases cholesterol efflux capacity in humans with the metabolic syndrome. Eur Heart J 36: 3020-3022.
81. Kinnunen PK and Ehnolm C (1976) Effect of serum and C-apoproteins from very low density lipoproteins on human postheparin plasma hepatic lipase. FEBS Lett 65: 354-357.
82. Koren MJ, Giugliano RP, Raal FJ, Sullivan D, Bolognese M, Langslet G, Civeira F, Somaratne R, Nelson P, and Liu T, et al.; OSLER Investigators (2014) Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia: 52-week results from the Open-Label Study of Long-Term Evaluation Against LDL-C (OSLER) randomized trial. Circulation 129: 234-243.
83. Koren MJ, Scott R, Kim JB, Knusel B, Liu T, Lei L, Bolognese M, and Wasserman SM (2012) Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study. Lancet 380: 1995-2006.
84. Kronenberg F and Utermann G (2013) Lipoprotein(a): resurrected by genetics. J Intern Med 273: 6-30.
85. Kühnast S, van der Tuin SJ, van der Hoorn JW, van Klinken JB, Simic B, Pieterman E, Havekes LM, Landmesser U, Lüscher TF, and Willems van Dijk K, et al. (2015) Anacetrapib reduces progression of atherosclerosis, mainly by reducing non-HDLcholesterol, improves lesion stability and adds to the beneficial effects of atorvastatin. Eur Heart J 36: 39-48.
86. Landray MJ, Haynes R, Hopewell JC, Parish S, Aung T, Tomson J, Wallendszus K, Craig M, Jiang L, and Collins R, et al.; HPS2-THRIVE Collaborative Group (2014) Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med 371: 203-212.
87. Larsson M, Vorrsjö E, Talmud P, Lookene A, and Olivecrona G (2013) Apolipoproteins C-I and C-III inhibit lipoprotein lipase activity by displacement of the enzyme from lipid droplets. J Biol Chem 288: 33997-34008.
88. Lee J and Hegele RA (2014) Abetalipoproteinemia and homozygous hypobetalipoproteinemia: a framework for diagnosis and management. J Inherit Metab Dis 37: 333-339.
89. Lindholm MW, Elmén J, Fisker N, Hansen HF, Persson R, Møller MR, and Rosenbohm C, Ørum H, Straarup EM, and Koch T (2012) PCSK9 LNA antisense oligonucleotides induce sustained reduction of LDL cholesterol in nonhuman primates. Mol Ther 20: 376-381.
90. Lipid Research Clinics (1984) The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA 251: 351-364.
91. MacLean PS, Bower JF, Vadlamudi S, Osborne JN, Bradfield JF, Burden HW, Bensch WH, Kauffman RF, and Barakat HA (2003) Cholesteryl ester transfer protein expression prevents diet-induced atherosclerotic lesions in male db/db mice. Arterioscler Thromb Vasc Biol 23: 1412-1415.
92. Madsen L, Rustan AC, Vaagenes H, Berge K, Dyrøy E, and Berge RK (1999) Eicosapentaenoic and docosahexaenoic acid affect mitochondrial and peroxisomal fatty acid oxidation in relation to substrate preference. Lipids 34: 951-963.
93. Marotti KR, Castle CK, Boyle TP, Lin AH, Murray RW, and Melchior GW (1993) Severe atherosclerosis in transgenic mice expressing simian cholesteryl ester transfer protein. Nature 364: 73-75.
94. Maxwell KN and Breslow JL (2004) Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype. Proc Natl Acad Sci USA 101: 7100-7105.
95. McKenney JM, Koren MJ, Kereiakes DJ, Hanotin C, Ferrand AC, and Stein EA (2012) Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy. J Am Coll Cardiol 59: 2344-2353.
96. Millar JS, Reyes-Soffer G, Jumes P, Dunbar RL, deGoma EM, Baer AL, Karmally W, Donovan DS, Rafeek H, and Pollan L, et al. (2015) Anacetrapib lowers LDL by increasing ApoB clearance in mildly hypercholesterolemic subjects. J Clin Invest 125: 2510-2522.
97. Morehouse LA, Sugarman ED, Bourassa PA, Sand TM, Zimetti F, Gao F, Rothblat GH, and Milici AJ (2007) Inhibition of CETP activity by torcetrapib reduces susceptibility to diet-induced atherosclerosis in New Zealand White rabbits. J Lipid Res 48: 1263-1272.
98. Nassoury N, Blasiole DA, Tebon Oler A, Benjannet S, Hamelin J, Poupon V, McPherson PS, Attie AD, Prat A, and Seidah NG (2007) The cellular trafficking of the secretory proprotein convertase PCSK9 and its dependence on the LDLR. Traffic 8: 718-732.
99. Navab M, Anantharamaiah GM, Hama S, Garber DW, Chaddha M, Hough G, Lallone R, and Fogelman AM (2002) Oral administration of an Apo A-I mimetic peptide synthesized from D-amino acids dramatically reduces atherosclerosis in mice independent of plasma cholesterol. Circulation 105: 290-292.
100. Nicholls SJ, Tuzcu EM, Brennan DM, Tardif JC, and Nissen SE (2008) Cholesteryl ester transfer protein inhibition, high-density lipoprotein raising, and progression of coronary atherosclerosis: insights from ILLUSTRATE (Investigation of Lipid Level Management Using Coronary Ultrasound to Assess Reduction of Atherosclerosis by CETP Inhibition and HDL Elevation). Circulation 118: 2506-2514.
101. Niesor EJ, Magg C, Ogawa N, Okamoto H, von der Mark E, Matile H, Schmid G, Clerc RG, Chaput E, and Blum-Kaelin D, et al. (2010) Modulating cholesteryl ester transfer protein activity maintains efficient pre-b-HDL formation and increases reverse cholesterol transport. J Lipid Res 51: 3443-3454.
102. Nieuwdorp M, Vergeer M, Bisoendial RJ, op 't Roodt J, Levels H, Birjmohun RS, Kuivenhoven JA, Basser R, Rabelink TJ, and Kastelein JJ, et al. (2008) Reconstituted HDL infusion restores endothelial function in patients with type 2 diabetes mellitus. Diabetologia 51: 1081-1084.
103. Nissen SE, Tsunoda T, Tuzcu EM, Schoenhagen P, Cooper CJ, Yasin M, Eaton GM, Lauer MA, Sheldon WS, and Grines CL, et al. (2003) Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA 290: 2292-2300.
104. Niu W and Qi Y (2015) Circulating cholesteryl ester transfer protein and coronary heart disease: mendelian randomization meta-analysis. Circ Cardiovasc Genet 8: 114-121.
105. Okamoto H, Yonemori F, Wakitani K, Minowa T, Maeda K, and Shinkai H (2000) A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits. Nature 406: 203-207.
106. Olivieri O, Bassi A, Stranieri C, Trabetti E, Martinelli N, Pizzolo F, Girelli D, Friso S, Pignatti PF, and Corrocher R (2003) Apolipoprotein C-III, metabolic syndrome, and risk of coronary artery disease. J Lipid Res 44: 2374-2381.
107. Park SW, Moon YA, and Horton JD (2004) Post-transcriptional regulation of low density lipoprotein receptor protein by proprotein convertase subtilisin/kexin type 9a in mouse liver. J Biol Chem 279: 50630-50638.
108. Pinkosky SL, Filippov S, Srivastava RA, Hanselman JC, Bradshaw CD, Hurley TR, Cramer CT, Spahr MA, Brant AF, and Houghton JL, et al. (2013) AMP-activated protein kinase and ATP-citrate lyase are two distinct molecular targets for ETC-1002, a novel small molecule regulator of lipid and carbohydrate metabolism. J Lipid Res 54: 134-151.
109. Plump AS, Masucci-Magoulas L, Bruce C, Bisgaier CL, Breslow JL, and Tall AR (1999) Increased atherosclerosis in ApoE and LDL receptor gene knock-out mice as a result of human cholesteryl ester transfer protein transgene expression. Arterioscler Thromb Vasc Biol 19: 1105-1110.
110. Plump AS, Scott CJ, and Breslow JL (1994) Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse. Proc Natl Acad Sci USA 91: 9607-9611.
111. Poirier S and Mayer G (2013) The biology of PCSK9 from the endoplasmic reticulum to lysosomes: new and emerging therapeutics to control low-density lipoprotein cholesterol. Drug Des Devel Ther 7: 1135-1148.
112. Raal F, Scott R, Somaratne R, Bridges I, Li G, Wasserman SM, and Stein EA (2012) Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial. Circulation 126: 2408-2417.
113. Raal FJ, Santos RD, Blom DJ, Marais AD, Charng MJ, Cromwell WC, Lachmann RH, Gaudet D, Tan JL, and Chasan-Taber S, et al. (2010) Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, doubleblind, placebo-controlled trial. Lancet 375: 998-1006.
114. Ridker PM, Paré G, Parker AN, Zee RY, Miletich JP, and Chasman DI (2009) Polymorphism in the CETP gene region, HDL cholesterol, and risk of future myocardial infarction: genomewide analysis among 18 245 initially healthy women from the Women's Genome Health Study. Circ Cardiovasc Genet 2: 26-33.
115. Rittershaus CW, Miller DP, Thomas LJ, Picard MD, Honan CM, Emmett CD, Pettey CL, Adari H, Hammond RA, and Beattie DT, et al. (2000) Vaccine-induced antibodies inhibit CETP activity in vivo and reduce aortic lesions in a rabbit model of atherosclerosis. Arterioscler Thromb Vasc Biol 20: 2106-2112.
116. Robinson JG, Farnier M, Krempf M, Bergeron J, Luc G, Averna M, Stroes ES, Langslet G, Raal FJ, and El Shahawy M, et al.; ODYSSEY LONG TERM Investigators (2015) Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med 372: 1489-1499.
117. Rosenson RS, Brewer HB Jr, Ansell BJ, Barter P, Chapman MJ, Heinecke JW, Kontush A, Tall AR, and Webb NR (2016) Dysfunctional HDL and atherosclerotic cardiovascular disease. Nat Rev Cardiol 13: 48-60.
118. Roth EM, McKenney JM, Hanotin C, Asset G, and Stein EA (2012) Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia. N Engl J Med 367: 1891-1900.
119. Rubin EM, Krauss RM, Spangler EA, Verstuyft JG, and Clift SM (1991) Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI. Nature 353: 265-267.
120. Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, Faas FH, Linares E, Schaefer EJ, and Schectman G, et al.; Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group (1999) Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 341: 410-418.
121. Rye KA and Barter PJ (2014) Cardioprotective functions of HDLs. J Lipid Res 55: 168-179.
122. Sabatine MS, Giugliano RP, Wiviott SD, Raal FJ, Blom DJ, Robinson J, Ballantyne CM, Somaratne R, Legg J, and Wasserman SM, et al.; Open-Label Study of Long-Term Evaluation against LDL Cholesterol (OSLER) Investigators (2015) Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med 372: 1500-1509.
123. Sacks FM, Rudel LL, Conner A, Akeefe H, Kostner G, Baki T, Rothblat G, de la Llera-Moya M, Asztalos B, and Perlman T, et al. (2009) Selective delipidation of plasma HDL enhances reverse cholesterol transport in vivo. J Lipid Res 50: 894-907.
124. Scandinavian Simvastatin Survival Study Group (1994) Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344: 1383-1389.
125. Schwartz GG, Olsson AG, Abt M, Ballantyne CM, Barter PJ, Brumm J, Chaitman BR, Holme IM, Kallend D, and Leiter LA, et al.; dal-OUTCOMES Investigators (2012) Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med 367: 2089-2099.
126. Seidah NG, Awan Z, Chrétien M, and Mbikay M (2014) PCSK9: a key modulator of cardiovascular health. Circ Res 114: 1022-1036.
127. Seidah NG, Benjannet S, Wickham L, Marcinkiewicz J, Jasmin SB, Stifani S, Basak A, Prat A, and Chretien M (2003) The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation. Proc Natl Acad Sci USA 100: 928-933.
128. Shah PK, Nilsson J, Kaul S, Fishbein MC, Ageland H, Hamsten A, Johansson J, Karpe F, and Cercek B (1998) Effects of recombinant apolipoprotein A-I(Milano) on aortic atherosclerosis in apolipoprotein E-deficient mice. Circulation 97: 780-785.
129. Sharp D, Blinderman L, Combs KA, Kienzle B, Ricci B, Wager-Smith K, Gil CM, Turck CW, Bouma ME, and Rader DJ, et al. (1993) Cloning and gene defects in microsomal triglyceride transfer protein associated with abetalipoproteinaemia. Nature 365: 65-69.
130. Shiomi M and Ito T (2001) MTP inhibitor decreases plasma cholesterol levels in LDL receptor-deficient WHHL rabbits by lowering the VLDL secretion. Eur J Pharmacol 431: 127-131.
131. Simic B, Hermann M, Shaw SG, Bigler L, Stalder U, Dörries C, Besler C, Lüscher TF, and Ruschitzka F (2012) Torcetrapib impairs endothelial function in hypertension. Eur Heart J 33: 1615-1624.
132. Sirtori CR, Calabresi L, Franceschini G, Baldassarre D, Amato M, Johansson J, Salvetti M, Monteduro C, Zulli R, and Muiesan ML, et al. (2001) Cardiovascular status of carriers of the apolipoprotein A-I(Milano) mutant: the Limone sul Garda study. Circulation 103: 1949-1954.
133. Spence JD and Koschinsky M (2012) Mechanisms of lipoprotein(a) pathogenicity: prothrombotic, proatherosclerotic, or both? Arterioscler Thromb Vasc Biol 32: 1550-1551.
134. Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E, and Fruchart JC (1998) Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 98: 2088-2093.
135. Staels B, Vu-Dac N, Kosykh VA, Saladin R, Fruchart JC, Dallongeville J, and Auwerx J (1995) Fibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase. A potential mechanism for the hypolipidemic action of fibrates. J Clin Invest 95: 705-712.
136. Stawowy P (2015) Proprotein convertases in atherogenesis. Curr Opin Lipidol 26: 338-344.
137. Stein EA, Gipe D, Bergeron J, Gaudet D, Weiss R, Dufour R, Wu R, and Pordy R (2012) Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial. Lancet 380: 29-36.
138. Stein EA, Giugliano RP, KorenMJ, Raal FJ, Roth EM, Weiss R, SullivanD, Wasserman SM, Somaratne R, and Kim JB, et al.; PROFICIO Investigators (2014) Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trials. Eur Heart J 35: 2249-2259.
139. Stitziel NO, Won HH, Morrison AC, Peloso GM, Do R, Lange LA, Fontanillas P, Gupta N, Duga S, and Goel A, et al.; Myocardial Infarction Genetics Consortium Investigators (2014) Inactivating mutations in NPC1L1 and protection from coronary heart disease. N Engl J Med 371: 2072-2082.
140. Sugano M, Makino N, Sawada S, Otsuka S, Watanabe M, Okamoto H, Kamada M, and Mizushima A (1998) Effect of antisense oligonucleotides against cholesteryl ester transfer protein on the development of atherosclerosis in cholesterol-fed rabbits. J Biol Chem 273: 5033-5036.
141. Sullivan D, Olsson AG, Scott R, Kim JB, Xue A, Gebski V, Wasserman SM, and Stein EA (2012) Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial. JAMA 308: 2497-2506.
142. Sviridov DO, Ikpot IZ, Stonik J, Drake SK, Amar M, Osei-Hwedieh DO, Piszczek G, Turner S, and Remaley AT (2011) Helix stabilization of amphipathic peptides by hydrocarbon stapling increases cholesterol efflux by the ABCA1 transporter. Biochem Biophys Res Commun 410: 446-451.
143. Tabet F, Lambert G, Cuesta Torres LF, Hou L, Sotirchos I, Touyz RM, Jenkins AJ, Barter PJ, and Rye KA (2011) Lipid-free apolipoprotein A-I and discoidal reconstituted high-density lipoproteins differentially inhibit glucose-induced oxidative stress in human macrophages. Arterioscler Thromb Vasc Biol 31: 1192-1200.
144. Tabet F, Remaley AT, Segaliny AI, Millet J, Yan L, Nakhla S, Barter PJ, Rye KA, and Lambert G (2010) The 5A apolipoprotein A-I mimetic peptide displays antiinflammatory and antioxidant properties in vivo and in vitro. Arterioscler Thromb Vasc Biol 30: 246-252.
145. Tardif JC, Ballantyne CM, Barter P, Dasseux JL, Fayad ZA, Guertin MC, Kastelein JJ, Keyserling C, Klepp H, and Koenig W, et al.; Can HDL Infusions Significantly Quicken Atherosclerosis REgression (CHI-SQUARE) Investigators (2014) Effects of the high-density lipoprotein mimetic agent CER-001 on coronary atherosclerosis in patients with acute coronary syndromes: a randomized trial. Eur Heart J 35: 3277-3286.
146. Tardif JC, Grégoire J, L'Allier PL, Ibrahim R, Lespérance J, Heinonen TM, Kouz S, Berry C, Basser R, and Lavoie MA, et al.; Effect of rHDL on Atherosclerosis-Safety and Efficacy (ERASE) Investigators (2007) Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial. JAMA 297: 1675-1682.
147. Thanassoulis G, Campbell CY, Owens DS, Smith JG, Smith AV, Peloso GM, Kerr KF, Pechlivanis S, Budoff MJ, and Harris TB, et al.; CHARGE Extracoronary Calcium Working Group (2013) Genetic associations with valvular calcification and aortic stenosis. N Engl J Med 368: 503-512.
148. Thies F, Garry JM, Yaqoob P, Rerkasem K, Williams J, Shearman CP, Gallagher PJ, Calder PC, and Grimble RF (2003) Association of n-3 polyunsaturated fatty acids with stability of atherosclerotic plaques: a randomised controlled trial. Lancet 361: 477-485.
149. Thompson A, Di Angelantonio E, Sarwar N, Erqou S, Saleheen D, Dullaart RP, Keavney B, Ye Z, and Danesh J (2008) Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk. JAMA 299: 2777-2788.
150. Thompson PD, Rubino J, Janik MJ, MacDougall DE, McBride SJ, Margulies JR, and Newton RS (2015) Use of ETC-1002 to treat hypercholesterolemia in patients with statin intolerance. J Clin Lipidol 9: 295-304.
151. Tsimikas S, Viney NJ, Hughes SG, Singleton W, Graham MJ, Baker BF, Burkey JL, Yang Q, Marcovina SM, and Geary RS, et al. (2015) Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study. Lancet 386: 1472-1483.
152. Tso C, Martinic G, Fan WH, Rogers C, Rye KA, and Barter PJ (2006) High-density lipoproteins enhance progenitor-mediated endothelium repair in mice. Arterioscler Thromb Vasc Biol 26: 1144-1149.
153. Urban D, Pöss J, Böhm M, and Laufs U (2013) Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis. J Am Coll Cardiol 62: 1401-1408.
154. van der Tuin SJ, Kühnast S, Berbée JF, Verschuren L, Pieterman EJ, Havekes LM, van der Hoorn JW, Rensen PC, Jukema JW, and Princen HM, et al. (2015) Anacetrapib reduces (V)LDL cholesterol by inhibition of CETP activity and reduction of plasma PCSK9. J Lipid Res 56: 2085-2093.
155. von Schacky C, Angerer P, Kothny W, Theisen K, and Mudra H (1999) The effect of dietary omega-3 fatty acids on coronary atherosclerosis. A randomized, doubleblind, placebo-controlled trial. Ann Intern Med 130: 554-562.
156. Waksman R, Torguson R, Kent KM, Pichard AD, Suddath WO, Satler LF, Martin BD, Perlman TJ, Maltais JA, and Weissman NJ, et al. (2010) A first-in-man, randomized, placebo-controlled study to evaluate the safety and feasibility of autologous delipidated high-density lipoprotein plasma infusions in patients with acute coronary syndrome. J Am Coll Cardiol 55: 2727-2735.
157. Wang CS, McConathy WJ, Kloer HU, and Alaupovic P (1985) Modulation of lipoprotein lipase activity by apolipoproteins. Effect of apolipoprotein C-III. J Clin Invest 75: 384-390.
158. Weintraub MS, Zechner R, Brown A, Eisenberg S, and Breslow JL (1988) Dietary polyunsaturated fats of the W-6 and W-3 series reduce postprandial lipoprotein levels. Chronic and acute effects of fat saturation on postprandial lipoprotein metabolism. J Clin Invest 82: 1884-1893.
159. Welder G, Zineh I, Pacanowski MA, Troutt JS, Cao G, and Konrad RJ (2010) High-dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol. J Lipid Res 51: 2714-2721.
160. Westerterp M, van der Hoogt CC, de Haan W, Offerman EH, Dallinga-Thie GM, Jukema JW, Havekes LM, and Rensen PC (2006) Cholesteryl ester transfer protein decreases high-density lipoprotein and severely aggravates atherosclerosis in APOE*3-Leiden mice. Arterioscler Thromb Vasc Biol 26: 2552-2559.
161. Wetterau JR, Aggerbeck LP, Bouma ME, Eisenberg C, Munck A, Hermier M, Schmitz J, Gay G, Rader DJ, and Gregg RE (1992) Absence of microsomal triglyceride transfer protein in individuals with abetalipoproteinemia. Science 258: 999-1001.
162. Windler E and Havel RJ (1985) Inhibitory effects of C apolipoproteins from rats and humans on the uptake of triglyceride-rich lipoproteins and their remnants by the perfused rat liver. J Lipid Res 26: 556-565.
163. Wu BJ, Chen K, Shrestha S, Ong KL, Barter PJ, and Rye KA (2013) High-density lipoproteins inhibit vascular endothelial inflammation by increasing 3b-hydroxysteroid-D24 reductase expression and inducing heme oxygenase-1. Circ Res 112: 278-288.
164. Wu BJ, Shrestha S, Ong KL, Johns D, Dunn LL, Hou L, Barter PJ, and Rye KA (2015a) Increasing HDL levels by inhibiting cholesteryl ester transfer protein activity in rabbits with hindlimb ischemia is associated with increased angiogenesis. Int J Cardiol 199: 204-212.
165. Wu BJ, Shrestha S, Ong KL, Johns D, Hou L, Barter PJ, and Rye KA (2015b) Cholesteryl ester transfer protein inhibition enhances endothelial repair and improves endothelial function in the rabbit. Arterioscler Thromb Vasc Biol 35: 628-636.
166. Yang J, Sato R, Goldstein JL, and Brown MS (1994) Sterol-resistant transcription in CHO cells caused by gene rearrangement that truncates SREBP-2. Genes Dev 8: 1910-1919.
167. Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Saito Y, Ishikawa Y, Oikawa S, Sasaki J, Hishida H, and Itakura H, et al.; Japan EPA Lipid Intervention Study (JELIS) Investigators (2007) Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet 369: 1090-1098.
168. Yvan-Charvet L, Kling J, Pagler T, Li H, Hubbard B, Fisher T, Sparrow CP, Taggart AK, and Tall AR (2010) Cholesterol efflux potential and antiinflammatory properties of high-density lipoprotein after treatment with niacin or anacetrapib. Arterioscler Thromb Vasc Biol 30: 1430-1438.
169. Yvan-Charvet L, Matsuura F, Wang N, Bamberger MJ, Nguyen T, Rinninger F, Jiang XC, Shear CL, and Tall AR (2007) Inhibition of cholesteryl ester transfer protein by torcetrapib modestly increases macrophage cholesterol efflux to HDL. Arterioscler Thromb Vasc Biol 27: 1132-1138.
170. Zaid A, Roubtsova A, Essalmani R, Marcinkiewicz J, Chamberland A, Hamelin J, Tremblay M, Jacques H, Jin W, and Davignon J, et al. (2008) Proprotein convertase subtilisin/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration. Hepatology 48: 646-654.
171. Zhang XL, Zhu QQ, Zhu L, Chen JZ, Chen QH, Li GN, Xie J, Kang LN, and Xu B (2015) Safety and efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 randomized, controlled trials. BMC Med 13: 123.